Current Report Filing (8-k)
February 03 2020 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): February 3, 2020
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in its
Charter)
Delaware
|
|
001-37526
|
|
26-0389433
|
(State
or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(Zip Code)
(484) 581-7505
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.001 par value per share
|
|
ZYNE
|
|
The
NASDAQ Global Market
|
Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
¨
Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
¨
Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
On February 3, 2020,
Zynerba Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the achievement of its patient
screening target in the Company’s pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children
and Adolescents with Fragile X) trial of Zygel in children and adolescents with Fragile X syndrome.
A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
The following exhibits
are being filed herewith:
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: February 3, 2020
|
ZYNERBA
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Suzanne Hanlon
|
|
|
Name:
Suzanne Hanlon
|
|
|
Title:
Secretary, Vice President and General Counsel
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024